United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

xellia pharmaceuticals aps - vancomycin hydrochloride - oral capsule - 125mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

xellia pharmaceuticals aps - vancomycin hydrochloride - oral capsule - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - caspofungin - pdr/conc/soln for infus - 50 milligram - other mycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - caspofungin - pdr/conc/soln for infus - 70 milligram - other mycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - daptomycin - powder for solution for injection/infusion - 350 milligram(s) - other antibacterials; daptomycin

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - daptomycin - powder for solution for injection/infusion - 500 milligram(s) - other antibacterials; daptomycin

United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals aps - bacitracin (unii: 58h6rwo52i) (bacitracin - unii:58h6rwo52i) - bacitracin 50000 [iu] - in accordance with the statements in the “warning box” the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - caspofungin - pdr/conc/soln for infus - 50 milligram - other mycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - caspofungin - pdr/conc/soln for infus - 70 milligram - other mycotics for systemic use